Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Clearside Biomedical, Inc.

Get SEC filing alerts via email and in your feed for Clearside Biomedical, Inc.

CLSD

Clearside Biomedical, Inc.

About Clearside Biomedical, Inc.

Clearside Biomedical develops innovative ophthalmic therapies and delivery platforms, primarily utilizing its proprietary suprachoroidal space injection technology. Its core product, XIPERE, treats macular edema associated with uveitis. The company partners globally for development and commercialization, leveraging its SCS Microinjector for targeted, non-surgical drug delivery to the back of the eye, aiming to improve efficacy, safety, and patient access in retinal and choroidal diseases.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Clearside Biomedical, Inc.

1
1
Clearside Biomedical, Inc. Clearside Biomedical Reports Q3 2025 Financial Results, Net Loss Decreases to $5.97 Million

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Clearside Biomedical, Inc. Clearside Biomedical Reports Revenue Growth but Continues to Face Net Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Clearside Biomedical, Inc. Clearside Biomedical Reports $8.2 Million Net Loss in Q1 2025, Revenue Increases to $2.3 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Clearside Biomedical, Inc. Clearside Biomedical Reports $34.4 Million Net Loss and Decreased Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Clearside Biomedical, Inc. Clearside Biomedical Reports Operating Losses, Strategic Developments, and Doubts Over Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments